Skip to main content

Table 1 The antiproliferative activities of the designed compounds (4a-4l)
figure a

From: Synthesis, design, biological evaluation, and computational analysis of some novel uracil-azole derivatives as cytotoxic agents

IC50 ± SD (µM)

IC50 ± SD (µM)

Entry

R

X

   

Entry

R

X

   
   

MCF-7

HEPG-2

MRC-5

   

MCF-7

HEPG-2

MRC-5

4a

Imidazole

H

150.5 ± 0.77

193.3 ± 7.98

 > 200

4g

2-Me-Imidazole

4-Br

109.2 ± 3.74

105.65 ± 3.03

 > 200

4b

Imidazole

3-Me

17.12 ± 1.30

48.47 ± 1.97

61.8 ± 2.30

4h

Triazole

H

131.4 ± 2.14

108.15 ± 10.81

 > 200

4c

Imidazole

4-Me

26.13 ± 4.41

27.18 ± 1.66

101.3 ± 3.02

4i

Triazole

3-Me

43.1 ± 2.07

65.40 ± 2.15

 > 200

4d

Imidazole

4-Br

130.63 ± 3.1

177.4 ± 4.06

 > 200

4j

Triazole

4-Me

16.18 ± 1.02

7.56 ± 5.28

57.3 ± 2.08

4e

2-Me-Imidazole

H

91.95 ± 2.19

ND

 > 200

4k

Triazole

4-Br

78.15 ± 4.64

56.42 ± 2.46

 > 200

4f

2-Me-Imidazole

4-Me

65.45 ± 3.1

55.85 ± 6.58

 > 200

4l

Triazole

H

67.55 ± 2.41

72.8 ± 2.19

 > 200

Cis platin

 

–

20.70 ± 0.83

15.91 ± 1.83

45.2 ± 2.5

      
  1. The number of compounds are shown with bold values (4a-4l)
  2. ND Not Determined
Back to article page

BMC Chemistry

ISSN: 2661-801X

Contact us